Matches in Wikidata for { <http://www.wikidata.org/entity/Q79508623> ?p ?o ?g. }
- Q79508623 description "article scientifique (publié 2007)" @default.
- Q79508623 description "artikull shkencor i botuar më 01 janar 2007" @default.
- Q79508623 description "artículu científicu espublizáu en xineru de 2007" @default.
- Q79508623 description "im Januar 2007 veröffentlichter wissenschaftlicher Artikel" @default.
- Q79508623 description "scientific article published on 01 January 2007" @default.
- Q79508623 description "wetenschappelijk artikel" @default.
- Q79508623 description "наукова стаття, опублікована в січні 2007" @default.
- Q79508623 name "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 name "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 name "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 type Item @default.
- Q79508623 label "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 label "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 label "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 prefLabel "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 prefLabel "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 prefLabel "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 P1433 Q79508623-4B781EEA-E527-4608-9139-AA416EC8FEF2 @default.
- Q79508623 P1476 Q79508623-D1BB23CB-EF92-4565-88AC-BC52E4ECF9B3 @default.
- Q79508623 P2093 Q79508623-0B2B55C0-6A1F-413F-8809-E2F28255623A @default.
- Q79508623 P2093 Q79508623-17978C8F-076B-4C9E-AB47-C5F2B9272280 @default.
- Q79508623 P2093 Q79508623-2081B87C-CC69-4373-9499-2A3E7039256E @default.
- Q79508623 P2093 Q79508623-29C84A19-3244-48AC-904C-72922CB5066A @default.
- Q79508623 P2093 Q79508623-365D0A2C-FECB-47CC-B2F8-75392FC0B3B8 @default.
- Q79508623 P2093 Q79508623-46686B46-6229-407C-8E22-234677D61094 @default.
- Q79508623 P2093 Q79508623-5DDEB2E3-753C-4D81-9B64-225520C47394 @default.
- Q79508623 P2093 Q79508623-AEA34666-0AF3-4ECE-9DBD-FA57FD1DAEF8 @default.
- Q79508623 P2093 Q79508623-D0D954FA-D9B7-4428-A619-8216A5631093 @default.
- Q79508623 P2093 Q79508623-F0B3D9F3-E0FC-4BA0-9FFE-71B42E9C7DD3 @default.
- Q79508623 P2860 Q79508623-031CCE1C-FCFE-4767-A18C-329CBF1AA1CC @default.
- Q79508623 P2860 Q79508623-0512D0B8-9327-47FD-BFF8-185BC1BA3C43 @default.
- Q79508623 P2860 Q79508623-0786EDBD-AA9B-493F-A781-73980FB88E04 @default.
- Q79508623 P2860 Q79508623-17C7822D-FAAA-40B3-8784-58004C4E4ABF @default.
- Q79508623 P2860 Q79508623-1FE86A6C-E158-4AB0-9175-1E9CB97C2DCA @default.
- Q79508623 P2860 Q79508623-298A3CFD-E76D-4514-B46F-8F7F72BE14D4 @default.
- Q79508623 P2860 Q79508623-3A10277B-4F79-40F8-8B61-BE525F746795 @default.
- Q79508623 P2860 Q79508623-3C5ADBD2-D004-43C2-ACCE-7A42C81E846F @default.
- Q79508623 P2860 Q79508623-49C6A2AD-20B2-42CB-B42D-A907A0F30949 @default.
- Q79508623 P2860 Q79508623-49DA2323-F569-48B5-9CD7-FA002E35A0CF @default.
- Q79508623 P2860 Q79508623-69E0D6E2-F59A-4A93-AF29-A9CEBDDFC43E @default.
- Q79508623 P2860 Q79508623-6AE7A2A1-22F6-4A55-87E9-F77A6C9BE967 @default.
- Q79508623 P2860 Q79508623-73431113-28A2-4BF8-B8BC-C4C873F0D2A0 @default.
- Q79508623 P2860 Q79508623-738EDA40-C738-4711-AD71-F51AB3F317DA @default.
- Q79508623 P2860 Q79508623-773B6327-45AA-429A-9799-C9E3EC94E85F @default.
- Q79508623 P2860 Q79508623-97490478-089E-4153-BBF9-F84BCECD9B78 @default.
- Q79508623 P2860 Q79508623-9B68A6CA-24EE-4468-A4C7-499810922C07 @default.
- Q79508623 P2860 Q79508623-AF7A3A2D-8C30-4A7D-9681-10463ABA1F9B @default.
- Q79508623 P2860 Q79508623-AFB2F6C3-0D51-481C-BFFE-78D66BA9C005 @default.
- Q79508623 P2860 Q79508623-B955A555-C18A-4CCE-954B-57B495BDF0D4 @default.
- Q79508623 P2860 Q79508623-C96D6127-5CB2-4E9D-A634-89C81F89732F @default.
- Q79508623 P2860 Q79508623-CED742E2-BAEC-4EFD-809F-EAC52461E0EC @default.
- Q79508623 P2860 Q79508623-E640E762-77A8-4EEE-9F2C-6AA5C3BF4AF5 @default.
- Q79508623 P2860 Q79508623-EE6C8BDA-A493-402F-BDA8-BF3F6FE57ADB @default.
- Q79508623 P2860 Q79508623-EEFC7663-0A10-474E-A0C0-3B05D2267B82 @default.
- Q79508623 P304 Q79508623-FD39D4D9-74A4-4AA2-9697-99134977FAF3 @default.
- Q79508623 P31 Q79508623-0556397A-8891-4DF1-8308-42E45288D9C6 @default.
- Q79508623 P356 Q79508623-885FE9CD-2AB0-4545-B51D-D01CD30C9886 @default.
- Q79508623 P433 Q79508623-423325DE-21C3-4F15-8156-8086E74D151C @default.
- Q79508623 P478 Q79508623-503CBC72-9AED-4FF3-B6DE-4EF740E47F1F @default.
- Q79508623 P577 Q79508623-99936CC8-7B4C-4F30-8490-9186E7A67491 @default.
- Q79508623 P698 Q79508623-6CA21D6A-A8D7-4EE4-A5F8-19B3FEA1A575 @default.
- Q79508623 P921 Q79508623-1B249690-C2C0-4874-BE04-860CBF9C7C1E @default.
- Q79508623 P921 Q79508623-4FB6FBEE-311F-4028-B15F-DA51750659CD @default.
- Q79508623 P921 Q79508623-97C1FBC5-196C-43D0-A77E-408127E1A91B @default.
- Q79508623 P921 Q79508623-C5DC7F21-398A-4C0C-9940-F6BE3F55DBA4 @default.
- Q79508623 P356 J.UROLONC.2006.02.016 @default.
- Q79508623 P698 17208138 @default.
- Q79508623 P1433 Q2113446 @default.
- Q79508623 P1476 "Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity" @default.
- Q79508623 P2093 "Brenda Wacker" @default.
- Q79508623 P2093 "Bruno Osterwalder" @default.
- Q79508623 P2093 "Ena Segota" @default.
- Q79508623 P2093 "Ming Zhou" @default.
- Q79508623 P2093 "Paul Elson" @default.
- Q79508623 P2093 "Robert Dreicer" @default.
- Q79508623 P2093 "Ronald M Bukowski" @default.
- Q79508623 P2093 "Tarek Mekhail" @default.
- Q79508623 P2093 "Thomas E Hutson" @default.
- Q79508623 P2093 "Thomas Olencki" @default.
- Q79508623 P2860 Q27860562 @default.
- Q79508623 P2860 Q29615133 @default.
- Q79508623 P2860 Q33337325 @default.
- Q79508623 P2860 Q34514696 @default.
- Q79508623 P2860 Q34519158 @default.
- Q79508623 P2860 Q34520221 @default.
- Q79508623 P2860 Q36621825 @default.
- Q79508623 P2860 Q40691493 @default.
- Q79508623 P2860 Q40890407 @default.
- Q79508623 P2860 Q43843476 @default.
- Q79508623 P2860 Q43859818 @default.
- Q79508623 P2860 Q43942757 @default.
- Q79508623 P2860 Q44042525 @default.
- Q79508623 P2860 Q44164191 @default.
- Q79508623 P2860 Q44187667 @default.
- Q79508623 P2860 Q44544385 @default.
- Q79508623 P2860 Q45090159 @default.
- Q79508623 P2860 Q47685389 @default.
- Q79508623 P2860 Q47832682 @default.
- Q79508623 P2860 Q53515076 @default.
- Q79508623 P2860 Q56019528 @default.